A3 Artists Hires Delsey Attardi As Digital Media Agent
EXCLUSIVE: A3 Artists Agency has hired Delsey Attardi as an agent in its Digital Media division. Attardi, who most recently worked as a digital endorsement agent at Buchwald, will report to A3 partner and division head Jade Sherman in the new role.
The move bolsters the company’s Digital Media unit which is among its largest, with 25 members now across its Los Angeles, New York and London offices. Attardi will bring clients including Lily Chee, Brooklynne Webb and Mireya Rios to join the A3 fold.
“Delsey brings to the table an impressive track record and experience working with Gen Z talent, including building strong rosters of digital creators and forming long-lasting relationships with buyers, ad agencies and brands,” A3 president Brian Cho said. “Her deep understanding of the everchanging digital media landscape will lend itself well to helping us continue providing the best possible service to our clients.”
Attardi spent the past five years at Buchwald, starting as an assistant in the commercial department before moving into the branding and licensing department. She was upped to agent there in 2018.
Read More About:
Netflix Up 3% Consequent To Acquisition Of Video Game Portal
Shares of online streaming platform Netflix, Inc. (NFLX) are up 3 percent on Thursday trading. The company recently acquired video game creator Night School Studio, thus becoming its first acquisition in the video game space, reports said.
Night School Studio was founded by Sean Krankel and Adam Hines in 2014. Night School Studio is best known for their critically acclaimed debut game, OXENFREE. “We’re in the early stages of creating a great gaming experience for our members around the world. So we’re excited to announce today Night School Studio is joining Netflix,” said Mike Verdu, VP, Game Development at Netflix, in a statement.
The game developer will most likely start working on a “Stranger Things” title right away.
Currently at $613.28, the stock has traded between $463.41 and $619.0 during the past 52 weeks.
FDA Approves AbbVie’s Qulipta For Preventive Treatment Of Migraine
The U.S. Food and Drug Administration approved AbbVie’s (ABBV) Qulipta or atogepant for the preventive treatment of episodic migraine in adults.
Qulipta is the first and only oral calcitonin gene-related peptide (CGRP) receptor antagonist (gepant) specifically developed for the preventive treatment of migraine, the company said in a statement.
The approval is supported by data from a clinical program evaluating the efficacy, safety and tolerability of QULIPTA in nearly 2,000 patients who experienced 4 to 14 migraine days per month, including the pivotal Phase 3 ADVANCE study, the pivotal Phase 2b/3 study, and the Phase 3 long-term safety study.
AbbVie noted that Qulipta demonstrated statistically significant, clinically meaningful rapid and continuous reductions in mean monthly migraine days among adults with episodic migraine compared to placebo across the 12-week treatment period with significant reductions seen in weeks 1-4.
The pivotal trial showed that when taking Qulipta, the majority of patients experienced between a 50-100% reduction in monthly migraine days across 12 week.
Migraine is a complex disease with recurrent attacks that are often incapacitating and characterized by severe, throbbing headache pain as well as compounding associated symptoms like extreme sensitivity to light, sound or nausea. It is highly prevalent, affecting more than 1 billion people worldwide, including 39 million people in the U.S. alone.
Allegion Adjusts FY21 Outlook On Supply Chain Constraints, Parts Shortages – Quick Facts
Allegion plc (ALLE) said widespread supply chain shortages and inflation have prompted adjustments to its full year 2021 reported outlook. The company said these challenges will temper its top-line growth and exert margin pressure for the balance of 2021.
For full-year 2021, the company now expects EPS to be in the range of $4.95 to $5.05, with adjusted EPS in the range of $5.00 to $5.10. In July, the company projected full-year EPS in a range of $5.15 to $5.30 and adjusted EPS in a range of $5.25 to $5.40.
Allegion now expects full-year 2021 revenue growth of 4 percent to 4.5 percent on a reported basis and 3 percent to 3.5 percent organically. Previously, the company projected full-year revenue growth in a range of 7 to 7.5 percent on a reported basis and 5.5 to 6 percent organically.
The company now estimates full-year available cash flow to be $460 million to $480 million.
Shares of Allegion plc were down 2.7% in pre-market trade on Friday.
Oil Edges Lower As Growth Worries Weigh
Crude prices edged lower Friday on concerns about the Chinese economy and signs of slowing global growth amid rising costs and heightened supply chain disruptions.
Traders also looked ahead to next week’s meeting of top producers for direction.
Benchmark Brent crude futures slipped half a percent to $77.94 in European trade, while U.S. crude futures were down 0.8 percent at $74.45.
Asia’s manufacturing activity broadly stagnated in September as pandemic-induced factory shutdowns and waning economic momentum in China weighed on the region’s economies, surveys showed earlier today.
Elsewhere, Eurozone manufacturing growth weakened in September as producers report a growing toll from supply chain headwinds, IHS Markit noted.
The Organization of the Petroleum Exporting Countries and allies led by Russia, a group known as OPEC+, are scheduled to meet on Monday, and speculation is rife that the cartel may go beyond its existing deal to boost production by 400,000 barrels per day (bpd) in November and December, given the backdrop of oil hovering near three-year highs.